PreMD files provisional patent application for new method of quantifying cancer biomarkers



The American Medical Association journal Archives of Pediatrics & Adolescent Medicine has published a new study by researchers at Cornell University indicating evidence of an environmental trigger for autism among genetically vulnerable children. It is the first peer-reviewed study to positively associate the prevalence of autism to a factor related to the levels of precipitation

Full Post: New evidence of an environmental trigger for autism

Predictive medicine company PreMD Inc. has announced that it has filed a provisional patent application that describes a new simplified method of quantifying immunohistochemical staining of biomarkers. The provisional patent application was filed with the United States Patent and Trademark office.

This application, based on PreMD’s existing colour measurement patents and patent applications, may facilitate more accurate and cost-effective detection of biomarkers in clinical specimens.

“With the news earlier this year of breast cancer patients being incorrectly diagnosed and treated based on erroneous interpretation of immunohistochemistry tests it immediately came to our minds that our existing intellectual property and expertise in colour measurement may be useful in improving this critical situation. Today I am pleased to say that we have made significant headway in developing this concept and have submitted a provisional patent application that may be used to improve the scoring of immunohistochemical reactions resulting in more accurate and cost-effective determination of test results” said Dr. Brent Norton, CEO of PreMD. “Biomarkers, detected in human tissue samples by immunohistochemistry, are playing an increasingly important role in prognosis and treatment decisions and the new methodology has the potential to be applicable to a broad range of such biomarkers. In the lab, with our limited budget, resources and test samples, we are getting accurate positive results in 90% of cases and full agreement in over 80% of all tests. To take this program to the next step we need to find a way, in these markets, to fund the development and testing,” he added.

http://www.premdinc.com

Link




Power3 Medical Products, Inc. said today that two CIP patent applications have been filed for BC-SeraPro Breast Cancer blood test and biomarkers by Dr. Ira Goldknopf, its president and Chief Scientific Officer. The applications for utility patents are entitled “Identities, Specificities, and Use of Twenty Two (22) Differentially Expressed Protein Biomarkers for Blood Based Diagnosis

Full Post: Power3 Medical files two patent applications for breast cancer blood test



Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix (cyclobenzaprine hydrochloride) extended-release capsules, 15mg and 30mg. Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of Amrix with the U.S.

Full Post: Barr Labs confirms patent challenge of Amrix extended-release capsules



Human Pheromone Sciences, Inc. has announced that it has filed a Comprehensive Patent Application with the International Bureau of the World Patent Office for the use of its innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships,

Full Post: HPS files world patent for mood-enhancing compound from sea coral



MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by the University of Melbourne. In

Full Post: MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders



Mylan Inc. has confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Cephalon Inc., Eurand Inc. and Anesta AG in connection with the filing of an Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg, the generic version of AMRIX Capsules. Mylan

Full Post: Mylan confirms first-to-file patent challenge of AMRIX capsules